DNA损伤反应抑制剂增强了瘤治疗场 (TTFields) 在质瘤类干细胞中的强度
Aurelie Vanderlinden1, Callum G Jones1, Katie N Myers1
1Division of Clinical Medicine, The University of Sheffield, School of Medicine and Population Health, Sheffield, S10 2RX, UK.
British journal of cancer
|September 30, 2023
概括
瘤治疗场 (TTFields) 疗法激活了质瘤干细胞中的DNA修复通路. 将TTFields与DNA损伤反应抑制剂和辐射相结合,显著增强了抗癌效应,为脑瘤提供了新的治疗策略.
科学领域:
- 神经瘤学神经瘤学
- 癌症生物学 癌症生物学
- 医学物理 医学物理
背景情况:
- 高度质瘤的存活率很低,尽管使用标准治疗.
- 瘤治疗场 (TTFields) 疗法通过破坏线粒分裂,显示出适度的生存益处.
- TTFields也可能影响DNA修复和复制,表明组合治疗的潜力.
研究的目的:
- 研究TTFields和DNA损伤反应抑制剂 (DDRi) 在质瘤类干细胞 (GSCs) 的联合作用.
- 评估基于TTFields的多模式治疗策略对质母细胞瘤的潜力.
主要方法:
- 利用患者衍生的GSC和临床前的TTFields系统.
- 与各种DDR抑制剂 (PARP1,ATR抑制剂) 结合使用TTFields.
- 评估了结合治疗,有和没有辐射,对细胞存活率和DNA损伤的影响.
主要成果:
- TTFields强有力的激活了PARP和ATR介导的DNA修复.
- 将TTFields与PARP1或ATR抑制剂相结合,显著降低了GSC的克隆性生存率.
- 辐射进一步增强了这些联合策略的效力,延迟了DNA损伤的解决.
结论:
- 这项研究是第一个报告TTFields与临床相关的DDRi结合在GSC模型中的研究.
- 这些发现支持TTFields和DDRi作为质母细胞瘤的有前途的多模式治疗策略.
- 对于这些目前无法治愈的脑瘤,需要进一步进行翻译性研究.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551


